By Naomi Jagoda
Robert Weissman, president of the consumer advocacy group Public Citizen, criticized the report.
“This is bad fiction,” he said.
For example, Weissman argued that the administration’s actions in the drug-pricing area have only had a trivial impact. He also argued that the report ignored benefits of regulations.